AbbVie Inc. (ABBV)
AbbVie in Settlement With Generic Drugmakers on Rinvoq
The biopharmaceutical company doesn't expect U.S. generic entry for the drug before 2037 now that it has settled litigation.
AbbVie: What's Happening With ABBV Stock?
AbbVie's stock is on the rise, and for good reason! The company just reached a major agreement with generic drug manufacturers to delay the release of a generic version of its blockbuster drug, Rinvoq, until 2037.
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
AbbVie (ABBV) closed at $210 in the latest trading session, marking a -1.2% move from the prior day.
J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.
Wall Street Week Ahead
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
AbbVie: Plenty Of Positives
AbbVie has had a good August, with double digit MoM gains after seeing weakness for six months. Factors like an EU-US deal on pharmaceuticals, recent results, improved guidance, positive outcomes in using Rinvoq to treat alopecia and even the expansion of its neuroscience portfolio support ABBV. However, the recent acquisition of a depression treatment candidate can impact the earnings outlook at a time when its market multiples already look stretched.
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression
AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter's lead pipeline candidate, bretisilocin (GM-2505), a novel therapy being developed for treating major depressive disorder(MDD).
AbbVie Is A Top Biotech Pick
Q2 earnings results were strong for AbbVie as top line growth is at a historically high level and operating margin expanded due to SG&A efficiencies. The company's Rinvoq drug has new market potential and U.S. manufacturing plans are likely to help mitigate tariff headwinds successfully. EPS guidance for the full year was raised and consensus estimates also show that the outlook for AbbVie is a strong one.
Best Dividend Kings: August 2025
Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued with expected long-term annualized returns of at least 10%, based on Dividend Yield Theory analysis. Recent dividend increases have modestly boosted the group's 2025 dividend growth rate, though it still trails last year's pace.
AbbVie Investors Beware: Strong Growth Potential, Rising Risks
AbbVie has delivered strong total returns and dividend growth over time. Additionally, it enjoys strong growth prospects. However, it also faces significant uncertainty and risks.
AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth
ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.
